BMS-986020 + Montelukast + Flurbiprofen + Digoxin
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-drug Interaction Study
Conditions
Drug-drug Interaction Study
Trial Timeline
Sep 1, 2014 → Nov 1, 2014
NCT ID
NCT02227173About BMS-986020 + Montelukast + Flurbiprofen + Digoxin
BMS-986020 + Montelukast + Flurbiprofen + Digoxin is a phase 1 stage product being developed by Bristol Myers Squibb for Drug-drug Interaction Study. The current trial status is completed. This product is registered under clinical trial identifier NCT02227173. Target conditions include Drug-drug Interaction Study.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02227173 | Phase 1 | Completed |
Competing Products
15 competing products in Drug-drug Interaction Study